drugset
Drugs / MVA-Mosaic
last change Mar 2022 re-read 9 days ago

MVA-Mosaic

Vaccine

Developed for
HIV infectious disease
Investigated by
Beth Israel Deaconess Medical Center · Janssen Vaccines & Prevention B.V. · US Military HIV Research Program · National Institute of Allergy and Infectious Diseases (NIAID) · Crucell Holland BV · International AIDS Vaccine Initiative
+1 more · Ragon Institute of MGH, MIT and Harvard

Trials 4

today NCT03307915 · Ph 1 NCT02919306 · Ph 1/2 NCT02315703 · Ph 1/2 NCT02218125 · Ph 1
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT03307915 Mar 2018 → Nov 2021 HIV infectious disease Janssen Vaccines & Prevention B.V. Completed No outcome recorded
Phase 1 NCT02218125 Sep 2014 → Nov 2015 — Crucell Holland BV Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT02919306 Sep 2016 → Sep 2018 HIV infectious disease Janssen Vaccines & Prevention B.V. Completed No outcome recorded
Phase 1/2 NCT02315703 Dec 2014 → Aug 2017 — Janssen Vaccines & Prevention B.V. Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as MVA-Mosaic ClinicalTrials.gov intervention name — accepted as the source's own label NCT02315703 ↗
3

NCT02218125 ↗

NCT02919306 ↗

NCT03307915 ↗
Modality Vaccine “modified vaccinia Ankara (MVA)-vectored HIV-1 bivalent mosaic immunogen vaccine” PMID 29669026 ↗ Jul 2018
Route Intramuscular “administered by intramuscular (IM) injection” NCT02218125 ↗